Entrada Therapeutics Says FDA Declines To Lift Clinical Hold On ENTR-601-44 IND Application
(RTTNews) - Biopharmaceutical company Entrada Therapeutics, Inc. (TRDA) announced Wednesday the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
Entrada plans to announce data from ENTR-601-44-101 in the second half of 2024.
The primary objective of Entrada's double-blind, single ascending dose Phase 1 clinical trial, which is expected to enroll approximately 40 participants, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers.
ENTR-601-44-101 will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.
Entrada was previously notified by the FDA that the IND for the Phase 1 clinical trial of ENTR-601-44 had been placed on clinical hold.
Despite providing additional information to the FDA, the Company was informed that the Agency declined to lift the clinical hold.
U.S. Dollar Drops After Powell's Speech
TSX Hits New Record High As Stocks Rally On Fed Rate Cut Hopes
Powell Says Outlook, Shifting Balance Of Risks 'May Warrant' Lower Rates
Bay Street Likely To Open On Mixed Note; Powell's Speech Eyed
Sensex, Nifty Snap Six-day Winning Streak On Tariff Concerns
FTSE 100 Down Slightly; Standard Chartered Shares Up Sharply
U.S. Dollar Rises Ahead Of Fed's Powell Speech
